Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival

Exclusion Criteria

• •History of Stevens-Johnson syndrome or ocular pemphigoid
• •Ocular or periocular malignancy
• •Non-healing epithelial defect of at least 0.5x0.5 mm in host corneal bed lasting ≥6 weeks preoperatively
• •Uncontrolled glaucoma
• •Currently on dialysis
• •Has received treatment with anti-VEGF agents (intraocular or systemic) within 45 days of study entry
• •Concurrent use of systemic anti-VEGF agents
• •Change in topical corticosteroid regimen within 14 days of transplantation
• •Use of systemic immunosuppressive for indication other than corneal graft rejection
• •Pregnancy (positive pregnancy test) or lactating
• •Pre-menopausal women not using adequate contraception (Reliable intrauterine devices, hormonal contraception or a spermicide in combination with a barrier method)
• •Uncontrolled hypertension defined as systolic blood pressure (BP) ≥150 or diastolic BP ≥90 mmHg
• •History of thromboembolic event within 12 months prior to study entry
• •Participation in another simultaneous medical investigation or trial